Updated:
Gansu Qizheng Industry Group
Gansu Qizheng Industry Group was established in 1993 in Lanzhou, China, by Lei Jufang. The group's wealth originates from Tibet Cheezheng Tibetan Medicine Co.,...
Gansu Qizheng Industry Group
Gansu Qizheng Industry Group was established in 1993 in Lanzhou, China, by Lei Jufang. The group's wealth originates from Tibet Cheezheng Tibetan Medicine Co., a Shenzhen-listed pharmaceutical company focused on the research, production, and sale of traditional Tibetan remedies, particularly pain-relief patches. Lei, a former pharmaceutical researcher, moved to Tibet in the early 1990s and built the company around the commercialization of a single herbal paste formula rooted in centuries-old Tibetan medical texts. The Group's strategy centers on verticals related to healthcare and wellness. Its primary deployment sits inside Tibet Cheezheng Tibetan Medicine, which remains the cash engine and principal portfolio asset. Beyond pharmaceuticals, operations extend to medicinal herb cultivation and processing, leveraging raw-ingredient supply chains in the Tibetan Plateau and Gansu province. The group also holds interests in health food manufacturing and branded functional products aimed at China's domestic consumer market. Geographic exposure is heavily skewed toward China's western provinces, with research and production bases primarily in Tibet and Gansu, supplemented by distribution networks reaching other regions of mainland China. The firm operates as a relatively opaque corporate structure, with limited public disclosure on total group assets or fund commitments. The flagship entity, Tibet Cheezheng Tibetan Medicine, has allowed the group to raise public market capital since its IPO around 2009, based on public Chinese regulatory filings and financial data providers. There is no evidence of independent private equity fund activity or an external asset management arm; operations appear to function through direct corporate holdings and subsidiary businesses rather than through LP commitments to outside funds. Lei Jufang remains the controlling shareholder and central decision-maker, per the firm's official communications. Structurally, Gansu Qizheng separates itself from typical family offices by functioning as a deeply operational conglomerate. There is no intermediary delegation to external managers; strategy and governance are embedded within the industrial companies themselves. The bridge between the founder's specialized knowledge of Tibetan medicine and the assembly of vertically integrated manufacturing and sales operations gives it a hard-to-replicate expertise in a niche with high regulatory and cultural barriers to entry.
General information
Firm type
Corporate Investor
Year founded
1993
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Lanzhou
Corporate office
Lanzhou, Gansu, China
Principals
Lei Jufang
Founder & Chairwoman
Sector focus
Frequently asked questions
Who runs investment decisions at Gansu Qizheng Industry Group?
Founder Lei Jufang exercises centralized control over both strategic direction and capital allocation. She serves as Chairwoman of the flagship listed entity, Tibet Cheezheng Tibetan Medicine, and remains the ultimate decision-maker within the holding group. There are no external CIOs or investment committees disclosed in public filings.
Where does the underlying wealth come from?
The wealth traces to the commercialization of traditional Tibetan medicine, specifically a pain-relief herbal patch that became the foundation for Tibet Cheezheng Tibetan Medicine. Lei Jufang developed the product after relocating to Tibet in the early 1990s, scaling it into a publicly traded enterprise on the Shenzhen Stock Exchange. The pharmaceutical listing unlocked significant shareholder value and remains the group's primary asset.
Is Gansu Qizheng structured as a family office or an operating business?
It operates overwhelmingly as a corporate conglomerate, not a financial family office. The group holds controlling stakes in operating businesses within healthcare, pharmaceuticals, and health food rather than acting as an allocator through external fund commitments. There is no indication of a separate investment entity managing diversified financial assets or third-party LP commitments.
Does the firm invest in venture capital or fund commitments?
No public record exists of venture capital direct investments, third-party fund commitments, or a corporate venture arm. The group appears to deploy capital exclusively through directly owned subsidiaries in its core therapeutic and wellness verticals, with no disclosed activity in external startup financing or limited partnerships with outside GPs.
Which sectors does Gansu Qizheng focus on?
Operations concentrate on three interconnected verticals: Tibetan medicine and pharmaceuticals, medicinal herb cultivation and processing, and functional health foods. The group's strategy stays close to its origin competency — research, production, and sale of products derived from Tibetan traditional medicine ingredients and formulations, primarily serving China's domestic market.
Does Gansu Qizheng maintain philanthropic structures?
Public disclosure on formal philanthropic entities is thin. Lei Jufang has occasionally been noted in Chinese media for contributions to cultural preservation and disaster relief in Gansu and Tibet regions, but no dedicated foundation or structured giving program has been consistently documented in available English-language sources.
How does the firm source its raw materials and maintain supply-chain advantage?
The group has invested in direct cultivation bases for medicinal herbs in the Tibetan Plateau and Gansu province, giving it some vertical integration from raw ingredient to finished drug product. This sourcing model differentiates it from generic pharmaceutical manufacturers and adds a defensible moat around the specialized ingredients required for Tibetan medicine formulations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: